US neurologists have issued major new guidance expanding who should receive preventive treatment for migraine and which medications should be considered first. The updated recommendations replace guidance from 2012 and reflect more than a decade of rapidly evolving migraine research and treatment options.
The expert panel behind the guideline systematically reviewed recent clinical trials and other evidence on migraine prevention. The recommendations were developed by the American Academy of Neurology and the American Headache Society and endorsed by the American Academy of Family Physicians.
Who should now get prevention?
The new guidance recommends that more people with disabling migraine be considered for preventive medication, even if they do not meet the criteria for chronic migraine. Chronic migraine is defined as headache occurring on at least 15 days a month for more than three months, with migraine features on at least eight days a month.
Under the updated recommendations, clinicians should offer preventive treatment to people who experience four or more migraine days per month or four or more moderate-to-severe headache days per month. Prevention should also be offered to people whose migraine causes substantial disability, including difficulties with work or everyday activities.
Many recent clinical trials of preventive medications have enrolled participants with at least four migraine days per month. Research has also identified monthly headache frequency as a predictor of progression to chronic migraine, and preventive treatments may help reduce the likelihood of episodic migraine becoming chronic.
A new generation of migraine drugs
The guideline highlights treatments targeting calcitonin gene-related peptide, or CGRP, among the options with strong evidence for migraine prevention. These newer medications were developed specifically to target biological pathways involved in migraine rather than being repurposed from conditions such as epilepsy or high blood pressure.
Recommended CGRP-targeting treatments include atogepant, erenumab, fremanezumab, galcanezumab and eptinezumab. Depending on the medication, treatment may involve oral tablets, self-administered injections or intravenous infusions.
Clinical trials have provided substantial evidence that these treatments can reduce monthly migraine days, while several also have favorable tolerability profiles. However, cost and insurance coverage can remain barriers for US patients, and the guideline recommends considering affordability and access when choosing treatment.
The role of older medications and Botox
The panel emphasizes that established preventive medications continue to have an important role, particularly when newer treatments are unavailable, unsuitable or too expensive.
For episodic migraine, medications supported by high or moderate confidence in evidence for efficacy include propranolol, topiramate and valproate, alongside atogepant, eptinezumab, erenumab, fremanezumab and galcanezumab.
For chronic migraine, recommended options include many of the same newer treatments, along with topiramate and valproate. OnabotulinumtoxinA, widely known by the brand name Botox, is also included as an option for chronic migraine.
Because patients can respond differently to preventive therapy, finding the most suitable medication may require trying more than one option. If one treatment does not provide sufficient benefit or produces unacceptable side effects, another class may still be effective.
Addressing medication overuse
The guideline also addresses frequent use of medications taken during individual migraine attacks. Preventive treatment should be offered to people who meet criteria for medication overuse or medication-overuse headache.
For these patients, the guidance recommends considering preventive treatments that already have evidence for efficacy in medication overuse or medication-overuse headache, including CGRP monoclonal antibodies, atogepant, onabotulinumtoxinA and topiramate.
Clinicians are also advised to regularly assess whether preventive treatment is working and adjust medication or dosage when necessary. Lifestyle and trigger management remain part of migraine care alongside medication.
How long should treatment be tried?
The updated guidance provides recommendations on how long patients should generally use a preventive medication before determining whether it is effective.
For most migraine preventive medications, clinicians should wait at least eight to 12 weeks at the recommended tolerated dose before assessing efficacy. For onabotulinumtoxinA injections, the guideline recommends waiting 24 weeks before evaluating the full response.
If treatment response remains inadequate, the dose may be optimized when appropriate or another preventive treatment considered. If side effects are unacceptable, clinicians can reduce the dose or offer an alternative medication.
Because migraine is a chronic condition whose frequency and severity can change over time, preventive treatment should also be reassessed periodically. Decisions about continuing, changing or eventually stopping treatment should take into account migraine frequency, disability, treatment response, side effects and patient preferences.
Implications for patients and doctors
Specialists hope the expanded guidance will help clinicians identify more people who could benefit from preventive treatment rather than waiting until migraine becomes extremely frequent or disabling.
Migraine is among the most common neurological disorders and a major cause of disability worldwide, particularly during working age. Effective preventive treatment can reduce the frequency of attacks and migraine-related disability, potentially improving everyday functioning and quality of life.
The expanded range of medications also gives doctors and patients more flexibility when choosing treatment. Decisions can take into account not only effectiveness but also side effects, other medical conditions, cost, insurance coverage and whether someone prefers an oral, injectable or intravenous treatment.
Researchers continue to investigate combination approaches involving CGRP-targeting therapies and other preventive treatments, as well as potential ways to predict which patients are most likely to respond to particular medications.
For now, the central message of the updated guideline is that preventive migraine treatment should be considered for a broader group of patients. People do not need to wait until migraine becomes chronic before discussing prevention with their doctor, and the growing range of available therapies provides more opportunities to find a treatment that works.
